What does DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE do?

DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE is a specialist medical practice in Asse. Private Limited, started on 3 March 2011, 1 establishment.

What is the address of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE?

The registered office of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE is located at Asbeekstraat 20, 1730 Asse.

Is DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE still active?

Yes. According to the CBE (30 September 2026) DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE is active, legal situation “Normale toestand”, started on 3 March 2011.

Is DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE registered on Peppol?

Yes, DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE is registered on the Peppol network with ID 0208:0834258101.

What is the enterprise number of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE?

The enterprise number of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE is BE0834258101.

When was DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE founded?

DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE was founded on 3 March 2011.

Who are the directors of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE?

According to the 2025 annual accounts, the directors of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE are: Brigitte De Lescluze.

Is DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 March 2011; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE make in 2025?

DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE posted a profit after taxes of € 128,150 in financial year 2025.

What is the revenue of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE?

As a small company, DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 212,528.

DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE (Private Limited)

Dossier DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE, printed on 30 September 2026 from databakkes.be/en/0834258101/dr-vroman-philippe-medische-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE from Asse, company number BE0834258101, closed financial year 2025 with a result of € 128,150 after tax. For that financial year DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE recorded a gross margin of € 212,528 and equity of € 370,738. Compared with financial year 2024, the result moved from € 83,492 to € 128,150. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 28, 2026.

What it is worth Growing

€ 370,738

▲ 53% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 128,150

▲ 53% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 203,663

▼ 22% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 358,338.

People and assets in 2025

Vehicles and equipment

€ 33,944

▼ 36% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 33,209

▼ 33% vs 2024

€ 16,703 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 4,887

▲ € 4,279 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 34,901

▲ 70% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 84,554 Gross margin 2022: € 84,554 First fiscal year in the series	€ 119,797 Gross margin 2023: € 119,797 ▲ 42% vs 2022 (€ 84,554) Favourable step	€ 145,522 Gross margin 2024: € 145,522 ▲ 21% vs 2023 (€ 119,797) Favourable step	€ 212,528 Gross margin 2025: € 212,528 ▲ 46% vs 2024 (€ 145,522) Favourable step	▲ 46%
Profit after taxes	€ 74,049 Profit after taxes 2022: € 74,049 First fiscal year in the series	€ 82,587 Profit after taxes 2023: € 82,587 ▲ 12% vs 2022 (€ 74,049) Favourable step	€ 83,492 Profit after taxes 2024: € 83,492 ▲ 1% vs 2023 (€ 82,587) Favourable step	€ 128,150 Profit after taxes 2025: € 128,150 ▲ 53% vs 2024 (€ 83,492) Favourable step	▲ 53%
Equity	€ 76,510 Equity 2022: € 76,510 First fiscal year in the series	€ 159,097 Equity 2023: € 159,097 ▲ 108% vs 2022 (€ 76,510) Favourable step	€ 242,588 Equity 2024: € 242,588 ▲ 52% vs 2023 (€ 159,097) Favourable step	€ 370,738 Equity 2025: € 370,738 ▲ 53% vs 2024 (€ 242,588) Favourable step	▲ 53%
Total debts	€ 98,471 Total debts 2022: € 98,471 First fiscal year in the series	€ 104,998 Total debts 2023: € 104,998 ▲ 7% vs 2022 (€ 98,471) Unfavourable step	€ 76,865 Total debts 2024: € 76,865 ▼ 27% vs 2023 (€ 104,998) Favourable step	€ 82,832 Total debts 2025: € 82,832 ▲ 8% vs 2024 (€ 76,865) Unfavourable step	▲ 8%
Cash	€ 166,385 Cash 2022: € 166,385 First fiscal year in the series	€ 183,739 Cash 2023: € 183,739 ▲ 10% vs 2022 (€ 166,385) Favourable step	€ 261,538 Cash 2024: € 261,538 ▲ 42% vs 2023 (€ 183,739) Favourable step	€ 203,663 Cash 2025: € 203,663 ▼ 22% vs 2024 (€ 261,538) Unfavourable step	▼ 22%
Land & buildings	€ 1,957 Land & buildings 2022: € 1,957 First fiscal year in the series	€ 0 Land & buildings 2023: € 0 ▼ 100% vs 2022 (€ 1,957) Unchanged	-	-
Retained profit	€ 64,110 Retained profit 2022: € 64,110 First fiscal year in the series	€ 146,697 Retained profit 2023: € 146,697 ▲ 129% vs 2022 (€ 64,110) Favourable step	€ 230,188 Retained profit 2024: € 230,188 ▲ 57% vs 2023 (€ 146,697) Favourable step	€ 358,338 Retained profit 2025: € 358,338 ▲ 56% vs 2024 (€ 230,188) Favourable step	▲ 56%
Dividend	€ 65,000 Dividend 2022: € 65,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 65,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 35,981 Bank debt 2022: € 35,981 First fiscal year in the series	€ 64,790 Bank debt 2023: € 64,790 ▲ 80% vs 2022 (€ 35,981) Unfavourable step	€ 49,296 Bank debt 2024: € 49,296 ▼ 24% vs 2023 (€ 64,790) Favourable step	€ 33,209 Bank debt 2025: € 33,209 ▼ 33% vs 2024 (€ 49,296) Favourable step	▼ 33%
Balance sheet total	€ 174,981 Balance sheet total 2022: € 174,981 First fiscal year in the series	€ 264,094 Balance sheet total 2023: € 264,094 ▲ 51% vs 2022 (€ 174,981) Unchanged	€ 319,453 Balance sheet total 2024: € 319,453 ▲ 21% vs 2023 (€ 264,094) Unchanged	€ 453,570 Balance sheet total 2025: € 453,570 ▲ 42% vs 2024 (€ 319,453) Unchanged	▲ 42%

Key figures of DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE?

What happened at DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 Brigitte De Lescluze stepped down as director. NBB
Apr 28, 2026 New annual accounts for financial year 2025: profit of € 128,150 (▲ 53% vs 2024). Source: NBB ↗
2021 Brigitte De Lescluze became a director. NBB
Mar 3, 2011 New establishment in Asse. KBO
Mar 3, 2011 Start of the company according to the CBE. KBO

In short

From € 74,049 profit in 2022 to € 128,150 profit in 2025.

Paid € 111,994 in corporate taxes since 2022.

Best year ever: 2025, with € 128,150 profit.

Paid out € 65,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE? We notify you, reason included.

Follow DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Directors

According to the 2025 annual accounts

Brigitte De Lescluze

Director

since 2021 · until 2031

Establishments

Establishment units

Physical locations of this company

Registered office

Asbeekstraat 20

1730 Asse

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0834.258.101
VAT number: BE 0834.258.101
Registered office: Asbeekstraat 20, 1730 Asse
Names & denominations: DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 3 March 2011
Peppol: Active · Active since 27 Mar 2026
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗

DR. VROMAN PHILIPPE, MEDISCHE ONCOLOGIE